Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, ARADyAL, Málaga, Spain.
Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):108-119. doi: 10.18176/jiaci.0629. Epub 2020 Jul 22.
Thematic cooperative health research networks (RETICS) are organizational structures promoted by the Instituto de Salud Carlos III of the Spanish Ministry of Science with the objective of carrying out cooperative research projects addressing challenges of general interest for society as a whole in the field of health care. The RETICS of Asthma, Adverse Drug Reactions, and Allergy (ARADyAL) received funding in 2016 for a 5-year program (2017-2021). ARADyAL integrates basic and clinical research in the areas of allergy, immunology, genetics, nanomedicine, pharmacology, and chemistry, with special interest in research on new biomarkers and the design and evaluation of new interventions for allergic patients with severe phenotypes. The consortium comprises 28 groups across Spain, including 171 clinical and basic researchers, 17 clinical groups that cover more than 10 000 000 patients of all ages from urban and rural areas and 11 basic groups active mostly at universities and research institutes. ARADyAL has proposed a research program organized into 3 different areas focusing on precision medicine, as follows: Program 1, Mechanisms and prediction of adverse drug reactions and allergic diseases; Program 2, Toward a precise diagnosis of allergic diseases; and Program 3, Predicting interventions in allergic diseases. There is also 1 common program dedicated to training. The network has a Steering Committee and an External Advisory Scientific Committee, which advise the global network coordinator, who has recognized expertise in the field. ARADyAL is a unique meeting point for clinicians and basic scientists who are already working in allergy.
专题合作健康研究网络(RETCs)是西班牙科学部卡洛斯三世研究所推动的组织结构,旨在开展合作研究项目,以应对整个社会在医疗保健领域的普遍利益挑战。哮喘、药物不良反应和过敏反应(ARADyAL)的 RETCs 在 2016 年获得了为期 5 年(2017-2021 年)的资助计划。ARADyAL 将过敏、免疫学、遗传学、纳米医学、药理学和化学等领域的基础和临床研究整合在一起,特别关注新生物标志物的研究以及针对严重表型过敏患者的新干预措施的设计和评估。该联盟由西班牙的 28 个小组组成,包括 171 名临床和基础研究人员、17 个覆盖城市和农村地区所有年龄段超过 1000 万患者的临床小组,以及 11 个主要活跃在大学和研究机构的基础小组。ARADyAL 提出了一个研究计划,该计划分为 3 个不同的领域,重点关注精准医学,具体如下:计划 1,药物不良反应和过敏疾病的机制和预测;计划 2,迈向过敏疾病的精确诊断;计划 3,预测过敏疾病的干预措施。还有 1 个共同计划致力于培训。该网络有一个指导委员会和一个外部咨询科学委员会,为全球网络协调员提供建议,协调员在该领域具有公认的专业知识。ARADyAL 是临床医生和基础科学家的独特聚会点,他们已经在过敏领域开展工作。